For a detailed comparison, see our semaglutide vs tirzepatide comparison page
Even without the diagnosis of BED, up to 60 percent of people with obesity report experiencing food noise or thinking about food constantly which leads to distress and dysregulated eating behaviors, like loss of control eating and binge eating
The FDA recommends watching for: A new lump or mass in neck Difficulty swallowing Persistent hoarseness in your voice Shortness of breath If you notice any of these, contact your doctor
On April 30, 2026, the FDA proposed formally excluding compounded semaglutide and tirzepatide from the rules that govern large-scale pharmacy compounding
With respect to skeletal repair, it has been examined in models of bone injury and structural defects
How does Semaglutide GLP-1 differ from other weight loss medications